TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of the Efficacy and Safety of Two ACTs Plus Primaquine for Uncomplicated Plasmodium Vivax Malaria in North Sumatera, Indonesia: 1 Year Followup
Brief Summary: This randomized clinical trial will be conducted in subjects with uncomplicated Plasmodium vivax malaria during November 2010 to March 2012. The aim of the study is to compare the efficacy and safety of artesunate-amodiaquine plus primaquine (AS-AQ + PQ) and dihydroartemisinin-piperaquine plus primaquine (DHP + PQ) in uncomplicated vivax malaria. The significance of the study is to find alternative drug for treating patients with vivax malaria in case the standard treatment is not available or become resistance. This study will give thorough information about the efficacy and safety of 2 artemisinin-based combination therapies (ACTs) in combination with primaquine. It will also inform the Indonesian Ministry of Health on their suggested policies for radical cure of vivax malaria, and provides evidence based treatment options for chloroquine resistant vivax malaria. This study will also provide information about prevalence of glucose-6-phosphate dehydrogenase (G6PD) deficiency and G6PD variants in North Sumatera population.


Options:
A: Arm Label: DHP+PQ; Type: EXPERIMENTAL; Interventions: Drug: Dihydroartemisinin/piperaquine + primaquine | Arm Label: AS-AQ +PQ; Type: ACTIVE_COMPARATOR; Interventions: Drug: Artesunate-amodiaquine + primaquine | Intervention Type: DRUG; Name: Dihydroartemisinin/piperaquine + primaquine; Assigned to Arm(s): DHP+PQ | Intervention Type: DRUG; Name: Artesunate-amodiaquine + primaquine; Assigned to Arm(s): AS-AQ +PQ
B: Arm Label: AM(LT); Type: ACTIVE_COMPARATOR; Interventions: Drug: AM(LT) | Arm Label: AM(FDC); Type: EXPERIMENTAL; Interventions: Drug: AM(FDC) | Arm Label: AL; Type: EXPERIMENTAL; Interventions: Drug: AL | Arm Label: DP; Type: EXPERIMENTAL; Interventions: Drug: DP | Arm Label: AA (FDC); Type: EXPERIMENTAL; Interventions: Drug: AA(FDC) | Intervention Type: DRUG; Name: AM(FDC); Assigned to Arm(s): AM(FDC) | Intervention Type: DRUG; Name: AM(LT); Assigned to Arm(s): AM(LT) | Intervention Type: DRUG; Name: AL; Assigned to Arm(s): AL | Intervention Type: DRUG; Name: DP; Assigned to Arm(s): DP | Intervention Type: DRUG; Name: AA(FDC); Assigned to Arm(s): AA (FDC)
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sulphadoxine-pyrimethamine (day 1: 500mg S&25mg P/20 kg), Drug: Artesunate (day 1,2,3: 4 mg/kg), Drug: Primaquine-base (day 3: 0.75 mg/kg) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo tablets | Intervention Type: DRUG; Name: Sulphadoxine-pyrimethamine (day 1: 500mg S&25mg P/20 kg); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Artesunate (day 1,2,3: 4 mg/kg); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Primaquine-base (day 3: 0.75 mg/kg); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo tablets; Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: primaquine; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of the Efficacy and Safety of Two ACTs Plus Primaquine for Uncomplicated Plasmodium Vivax Malaria in North Sumatera, Indonesia: 1 Year Followup
Brief Summary: This randomized clinical trial will be conducted in subjects with uncomplicated Plasmodium vivax malaria during November 2010 to March 2012. The aim of the study is to compare the efficacy and safety of artesunate-amodiaquine plus primaquine (AS-AQ + PQ) and dihydroartemisinin-piperaquine plus primaquine (DHP + PQ) in uncomplicated vivax malaria. The significance of the study is to find alternative drug for treating patients with vivax malaria in case the standard treatment is not available or become resistance. This study will give thorough information about the efficacy and safety of 2 artemisinin-based combination therapies (ACTs) in combination with primaquine. It will also inform the Indonesian Ministry of Health on their suggested policies for radical cure of vivax malaria, and provides evidence based treatment options for chloroquine resistant vivax malaria. This study will also provide information about prevalence of glucose-6-phosphate dehydrogenase (G6PD) deficiency and G6PD variants in North Sumatera population.


Options:
A: Arm Label: DHA-P 7 days; Type: EXPERIMENTAL; Interventions: Drug: Dihydroartemisinin-Piperaquine | Arm Label: DHA-P 14 days; Type: EXPERIMENTAL; Interventions: Drug: Dihydroartemisinin-Piperaquine | Arm Label: Chloroquine 7 days; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chloroquine | Arm Label: Chloroquine 14 days; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chloroquine | Intervention Type: DRUG; Name: Dihydroartemisinin-Piperaquine; Assigned to Arm(s): DHA-P 7 days | Intervention Type: DRUG; Name: Dihydroartemisinin-Piperaquine; Assigned to Arm(s): DHA-P 14 days | Intervention Type: DRUG; Name: Chloroquine; Assigned to Arm(s): Chloroquine 7 days | Intervention Type: DRUG; Name: Chloroquine; Assigned to Arm(s): Chloroquine 14 days
B: Intervention Type: DRUG; Name: primaquine; Assigned to Arm(s): N/A
C: Arm Label: Primaquine; Type: EXPERIMENTAL; Interventions: Drug: Primaquine | Intervention Type: DRUG; Name: Primaquine; Assigned to Arm(s): Primaquine
D: Arm Label: DHP+PQ; Type: EXPERIMENTAL; Interventions: Drug: Dihydroartemisinin/piperaquine + primaquine | Arm Label: AS-AQ +PQ; Type: ACTIVE_COMPARATOR; Interventions: Drug: Artesunate-amodiaquine + primaquine | Intervention Type: DRUG; Name: Dihydroartemisinin/piperaquine + primaquine; Assigned to Arm(s): DHP+PQ | Intervention Type: DRUG; Name: Artesunate-amodiaquine + primaquine; Assigned to Arm(s): AS-AQ +PQ

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Vitamin D Supplementation Enhances Immune Response to BCG Vaccination in Infants
Brief Summary: The purpose of this study is to determine whether a single oral dose of vitamin D given to infants prior to Bacille-Calmette-Guerin (BCG) vaccination will enhance the immune response to BCG vaccination.


Options:
A: Arm Label: Vitamin D3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 (cholecalciferol) | Arm Label: Placebo; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3 (cholecalciferol); Assigned to Arm(s): Vitamin D3
B: Arm Label: Vitamin D; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin D | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Vitamin D | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D; Assigned to Arm(s): Placebo, Vitamin D
C: Arm Label: Usual care group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: High Dose Group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Cholecalciferol | Intervention Type: DIETARY_SUPPLEMENT; Name: Cholecalciferol; Assigned to Arm(s): High Dose Group
D: Arm Label: Maternal and Neonatal Intervention Arm; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D | Arm Label: Maternal and Neonatal Control Arm; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D; Assigned to Arm(s): Maternal and Neonatal Intervention Arm | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Maternal and Neonatal Control Arm

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Smoking Cessation in Hospitalized Smokers
Brief Summary: When smokers are hospitalized they quit smoking, either voluntarily or involuntarily. Most of them, however, go back to smoking soon after discharge. This study will test an innovative approach which includes dispensing nicotine patches at discharge, providing proactive telephone counseling post discharge, or giving a combination of the two. The interventions are aimed at increasing the long term quit rate of these patients.

The specific aims of the study are to demonstrate the effects of two interventions, dispensing nicotine patches at discharge and providing proactive telephone counseling soon after discharge, on 12-month quit rates of hospitalized smokers in a 2 x 2 factorial design.


Options:
A: Arm Label: Clinic Quality Improvement + Behavioral Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Clinic Quality Improvement + Behavioral Counseling | Arm Label: Clinic Quality Improvement + Attention Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Clinic Quality Improvement + Attention Control | Intervention Type: BEHAVIORAL; Name: Clinic Quality Improvement + Behavioral Counseling; Assigned to Arm(s): Clinic Quality Improvement + Behavioral Counseling | Intervention Type: BEHAVIORAL; Name: Clinic Quality Improvement + Attention Control; Assigned to Arm(s): Clinic Quality Improvement + Attention Control
B: Arm Label: Incentives; Type: EXPERIMENTAL; Interventions: Behavioral: NH Medicaid Incentives Program | Arm Label: No Incentives; Type: EXPERIMENTAL; Interventions: Behavioral: NH Medicaid Incentives Program | Intervention Type: BEHAVIORAL; Name: NH Medicaid Incentives Program; Assigned to Arm(s): Incentives, No Incentives
C: Arm Label: Telephone Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Telephone Counseling, Behavioral: Brief Hospital Counseling | Arm Label: Nicotine Patches; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patches, Behavioral: Brief Hospital Counseling | Arm Label: Telephone Counseling + Patches; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patches, Behavioral: Telephone Counseling, Behavioral: Brief Hospital Counseling | Arm Label: Brief hospital counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Brief Hospital Counseling | Intervention Type: DRUG; Name: Nicotine Patches; Assigned to Arm(s): Nicotine Patches, Telephone Counseling + Patches | Intervention Type: BEHAVIORAL; Name: Telephone Counseling; Assigned to Arm(s): Telephone Counseling, Telephone Counseling + Patches | Intervention Type: BEHAVIORAL; Name: Brief Hospital Counseling; Assigned to Arm(s): Brief hospital counseling, Nicotine Patches, Telephone Counseling, Telephone Counseling + Patches
D: Arm Label: Assisted Referral & IVR; Type: EXPERIMENTAL; Interventions: Behavioral: Assisted referral & IVR | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Assisted referral & IVR; Assigned to Arm(s): Assisted Referral & IVR

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Smoking Cessation in Hospitalized Smokers
Brief Summary: When smokers are hospitalized they quit smoking, either voluntarily or involuntarily. Most of them, however, go back to smoking soon after discharge. This study will test an innovative approach which includes dispensing nicotine patches at discharge, providing proactive telephone counseling post discharge, or giving a combination of the two. The interventions are aimed at increasing the long term quit rate of these patients.

The specific aims of the study are to demonstrate the effects of two interventions, dispensing nicotine patches at discharge and providing proactive telephone counseling soon after discharge, on 12-month quit rates of hospitalized smokers in a 2 x 2 factorial design.


Options:
A: Arm Label: Telephone Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Telephone Counseling, Behavioral: Brief Hospital Counseling | Arm Label: Nicotine Patches; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patches, Behavioral: Brief Hospital Counseling | Arm Label: Telephone Counseling + Patches; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patches, Behavioral: Telephone Counseling, Behavioral: Brief Hospital Counseling | Arm Label: Brief hospital counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Brief Hospital Counseling | Intervention Type: DRUG; Name: Nicotine Patches; Assigned to Arm(s): Nicotine Patches, Telephone Counseling + Patches | Intervention Type: BEHAVIORAL; Name: Telephone Counseling; Assigned to Arm(s): Telephone Counseling, Telephone Counseling + Patches | Intervention Type: BEHAVIORAL; Name: Brief Hospital Counseling; Assigned to Arm(s): Brief hospital counseling, Nicotine Patches, Telephone Counseling, Telephone Counseling + Patches
B: Arm Label: virtual reality exposure therapy (VRET); Type: EXPERIMENTAL; Interventions: Other: virtual reality exposure treatment | Arm Label: cognitive and behavioral approaches therapy without VRET; Type: EXPERIMENTAL; Interventions: Other: cognitive and behavioral approaches therapy | Intervention Type: OTHER; Name: virtual reality exposure treatment; Assigned to Arm(s): virtual reality exposure therapy (VRET) | Intervention Type: OTHER; Name: cognitive and behavioral approaches therapy; Assigned to Arm(s): cognitive and behavioral approaches therapy without VRET
C: Arm Label: SBT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supportive Behavioral Therapy | Arm Label: CBT; Type: EXPERIMENTAL; Interventions: Behavioral: CBT addressing postpartum mood and weight concerns | Intervention Type: BEHAVIORAL; Name: CBT addressing postpartum mood and weight concerns; Assigned to Arm(s): CBT | Intervention Type: BEHAVIORAL; Name: Supportive Behavioral Therapy; Assigned to Arm(s): SBT
D: Arm Label: Longitudinal Care; Type: EXPERIMENTAL; Interventions: Behavioral: smoking cessation | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: smoking cessation | Intervention Type: BEHAVIORAL; Name: smoking cessation; Assigned to Arm(s): Longitudinal Care, Usual Care

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Smoking Cessation in Hospitalized Smokers
Brief Summary: When smokers are hospitalized they quit smoking, either voluntarily or involuntarily. Most of them, however, go back to smoking soon after discharge. This study will test an innovative approach which includes dispensing nicotine patches at discharge, providing proactive telephone counseling post discharge, or giving a combination of the two. The interventions are aimed at increasing the long term quit rate of these patients.

The specific aims of the study are to demonstrate the effects of two interventions, dispensing nicotine patches at discharge and providing proactive telephone counseling soon after discharge, on 12-month quit rates of hospitalized smokers in a 2 x 2 factorial design.


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Smoking cessation program; Type: EXPERIMENTAL; Interventions: Other: Smoking cessation program | Intervention Type: OTHER; Name: Smoking cessation program; Assigned to Arm(s): Smoking cessation program
B: Arm Label: Telephone Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Telephone Counseling, Behavioral: Brief Hospital Counseling | Arm Label: Nicotine Patches; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patches, Behavioral: Brief Hospital Counseling | Arm Label: Telephone Counseling + Patches; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patches, Behavioral: Telephone Counseling, Behavioral: Brief Hospital Counseling | Arm Label: Brief hospital counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Brief Hospital Counseling | Intervention Type: DRUG; Name: Nicotine Patches; Assigned to Arm(s): Nicotine Patches, Telephone Counseling + Patches | Intervention Type: BEHAVIORAL; Name: Telephone Counseling; Assigned to Arm(s): Telephone Counseling, Telephone Counseling + Patches | Intervention Type: BEHAVIORAL; Name: Brief Hospital Counseling; Assigned to Arm(s): Brief hospital counseling, Nicotine Patches, Telephone Counseling, Telephone Counseling + Patches
C: Arm Label: Brief Treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine polacrilex, Bupropion | Arm Label: Extended NRT; Type: EXPERIMENTAL; Interventions: Drug: Nicotine polacrilex, Bupropion | Arm Label: Tailored/No Extended NRT; Type: EXPERIMENTAL; Interventions: Drug: Nicotine polacrilex, Bupropion | Arm Label: Extended Tailored Counseling + NRT; Type: EXPERIMENTAL; Interventions: Drug: Nicotine polacrilex, Bupropion | Intervention Type: DRUG; Name: Nicotine polacrilex, Bupropion; Assigned to Arm(s): Brief Treatment, Extended NRT, Extended Tailored Counseling + NRT, Tailored/No Extended NRT
D: Intervention Type: BEHAVIORAL; Name: smoking cessation intervention; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: counseling intervention; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: internet-based intervention; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Physician-Based Trial to Increase Colorectal Cancer Screening in Chinese
Brief Summary: The objective of this study is to test whether a culturally-tailored in-office based intervention have impact on increasing Chinese physician's recommendation of colorectal cancer (CRC) screening to their nonadherent Chinese patients.

Special aims are to:

1. Evaluate the efficacy of a culturally-tailored physician intervention on increasing non-adherent Chinese American's patients' CRC screening rate.
2. Identify factors that mediate or moderate the intervention effects. For example, patients who hold an eastern cultural view or are less acculturated will be more likely to benefit from the intervention than patients who hold a western view or who are more acculturated.


Options:
A: Arm Label: Mailed printed materials and in-office training; Type: EXPERIMENTAL; Interventions: Behavioral: Mailed printed materials and in-office training | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mailed printed materials and in-office training; Assigned to Arm(s): Mailed printed materials and in-office training
B: Arm Label: Fecal Occult Blood Test; Type: ACTIVE_COMPARATOR; Interventions: Other: Fecal occult blood test | Arm Label: Virtual Colonoscopy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Virtual colonoscopy | Arm Label: Optical Colonoscopy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Optical colonoscopy | Intervention Type: OTHER; Name: Fecal occult blood test; Assigned to Arm(s): Fecal Occult Blood Test | Intervention Type: PROCEDURE; Name: Virtual colonoscopy; Assigned to Arm(s): Virtual Colonoscopy | Intervention Type: PROCEDURE; Name: Optical colonoscopy; Assigned to Arm(s): Optical Colonoscopy
C: Arm Label: telephone; Type: EXPERIMENTAL; Interventions: Behavioral: telephone | Arm Label: face-to-face; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: consultation face-to-face | Intervention Type: BEHAVIORAL; Name: telephone; Assigned to Arm(s): telephone | Intervention Type: BEHAVIORAL; Name: consultation face-to-face; Assigned to Arm(s): face-to-face
D: Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: non needle control; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Accupuncture | Arm Label: Acupuncture - Standardized Points; Type: SHAM_COMPARATOR; Interventions: Procedure: Accupuncture | Arm Label: Accupunture - Experimental Points; Type: EXPERIMENTAL; Interventions: Procedure: Accupuncture | Intervention Type: PROCEDURE; Name: Accupuncture; Assigned to Arm(s): Accupunture - Experimental Points, Acupuncture - Standardized Points, non needle control

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Lower Limb Ischaemic Preconditioning on Renal Function in Patients Undergoing Living Donor Kidney Transplantation
Brief Summary: The purpose of this study was to investigate whether lower limb ischaemic preconditioning can improve renal function in patients undergoing living donor kidney transplantation


Options:
A: Intervention Type: PROCEDURE; Name: remote ischemic preconditioning; Assigned to Arm(s): N/A
B: Intervention Type: PROCEDURE; Name: remote ischemic preconditioning; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: remote ischemic postconditioning | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: remote ischemic postconditioning | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Procedure: remote ischemic postconditioning | Intervention Type: PROCEDURE; Name: remote ischemic postconditioning; Assigned to Arm(s): 1, 2, 3
D: Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: donor; Type: EXPERIMENTAL; Interventions: Device: remote ischaemic preconditioning | Arm Label: recipient; Type: EXPERIMENTAL; Interventions: Device: remote ischaemic preconditioning | Intervention Type: DEVICE; Name: remote ischaemic preconditioning; Assigned to Arm(s): donor, recipient

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Active-control, Double-blind, Double-dummy Study to Evaluate the Efficacy and Safety of Tafenoquine for the Treatment of Plasmodium Vivax in Adults
Brief Summary: This Phase II study is designed to determine whether a single 600 mg dose or 400mg/day for 3 days of tafenoquine is efficacious, and well tolerated for clearing P. vivax malaria infection (blood schizontocidal and gametocytocidal activity) and preventing P. vivax relapse (hypnozoite eradication). It will also further establish the safety and tolerability of these doses of tafenoquine.


Options:
A: Arm Label: DHA-P 7 days; Type: EXPERIMENTAL; Interventions: Drug: Dihydroartemisinin-Piperaquine | Arm Label: DHA-P 14 days; Type: EXPERIMENTAL; Interventions: Drug: Dihydroartemisinin-Piperaquine | Arm Label: Chloroquine 7 days; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chloroquine | Arm Label: Chloroquine 14 days; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chloroquine | Intervention Type: DRUG; Name: Dihydroartemisinin-Piperaquine; Assigned to Arm(s): DHA-P 7 days | Intervention Type: DRUG; Name: Dihydroartemisinin-Piperaquine; Assigned to Arm(s): DHA-P 14 days | Intervention Type: DRUG; Name: Chloroquine; Assigned to Arm(s): Chloroquine 7 days | Intervention Type: DRUG; Name: Chloroquine; Assigned to Arm(s): Chloroquine 14 days
B: Arm Label: Primaquine 7 day; Type: EXPERIMENTAL; Interventions: Drug: Primaquine | Arm Label: Placebo controlled arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Primaquine 14 day; Type: ACTIVE_COMPARATOR; Interventions: Drug: Primaquine | Intervention Type: DRUG; Name: Primaquine; Assigned to Arm(s): Primaquine 14 day | Intervention Type: DRUG; Name: Primaquine; Assigned to Arm(s): Primaquine 7 day | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo controlled arm
C: Arm Label: Primaquine; Type: EXPERIMENTAL; Interventions: Drug: Primaquine | Intervention Type: DRUG; Name: Primaquine; Assigned to Arm(s): Primaquine
D: Arm Label: Cohort 1 Tafenoquine; Type: EXPERIMENTAL; Interventions: Drug: Tafenoquine | Arm Label: Cohort 1-Chloroquine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chloroquine + Primaquine | Arm Label: Cohort 2 Tafenoquine; Type: EXPERIMENTAL; Interventions: Drug: tafenoquine | Arm Label: Cohort 2 Chloroquine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chloroquine + Primaquine | Intervention Type: DRUG; Name: Tafenoquine; Assigned to Arm(s): Cohort 1 Tafenoquine | Intervention Type: DRUG; Name: Chloroquine + Primaquine; Assigned to Arm(s): Cohort 1-Chloroquine | Intervention Type: DRUG; Name: tafenoquine; Assigned to Arm(s): Cohort 2 Tafenoquine | Intervention Type: DRUG; Name: Chloroquine + Primaquine; Assigned to Arm(s): Cohort 2 Chloroquine

Answer: D